Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
CH

NASDAQ · CHRS

Coherus Oncology, Inc.

Healthcare · Biotechnology

$1.34

Up+$0.02 (+1.52%)

Updated Sep 11, 2026, 5:00 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
165.18M
P/E ratio
1.07
Dividend yield
0.00%
52-week range
$1.13 – $2.11
Volume
1.02M
Avg. volume
1.23M

Price performance

CHRS price history

1M range · 20 trading sessions · Daily adjusted prices

CHRS closed at $1.34 after 20 trading sessions, up 17.54% for the selected period.

Last close
$1.34
Period change
+17.54%
Period low
$1.14
Period high
$1.46
Daily close
View OHLC price history
CHRS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$1.33$1.36$1.30$1.341.02M
Sep 9, 2026$1.34$1.375$1.31$1.32840.62K
Sep 8, 2026$1.40$1.43$1.36$1.37549.2K
Sep 4, 2026$1.38$1.435$1.38$1.42306.06K
Sep 3, 2026$1.42$1.43$1.36$1.37437.2K
Sep 2, 2026$1.37$1.435$1.355$1.42621.49K
Sep 1, 2026$1.36$1.40$1.35$1.37695.16K
Aug 31, 2026$1.39$1.41$1.30$1.351.13M
Aug 28, 2026$1.45$1.48$1.40$1.41605.09K
Aug 27, 2026$1.43$1.48$1.41$1.46788.32K
Aug 26, 2026$1.37$1.455$1.34$1.45896.54K
Aug 25, 2026$1.36$1.4099$1.31$1.371.3M
Aug 24, 2026$1.43$1.43$1.35$1.361.05M
Aug 21, 2026$1.32$1.44$1.315$1.421.57M
Aug 20, 2026$1.31$1.34$1.27$1.32740.19K
Aug 19, 2026$1.379$1.405$1.295$1.333.04M
Aug 18, 2026$1.26$1.36$1.22$1.343.48M
Aug 17, 2026$1.20$1.2001$1.13$1.151.26M
Aug 14, 2026$1.16$1.205$1.14$1.20648.33K
Aug 13, 2026$1.18$1.195$1.13$1.141.06M

Latest CHRS news

The latest Smart Investors Daily articles mentioning CHRS.

Stock researchCompany · Overview

CHRS research

Overview

Company profile and research snapshot.

Company profile

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.02
Implied upside
—
Analysts
—
CHRS recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
May 11, 2026GuggenheimBuy—
Jan 22, 2026OppenheimerOutperform—
Sep 4, 2025Maxim GroupBuy—
Apr 29, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Coherus to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.Morgan Stanley 24th Annual Global Healthcare Confere

Yahoo · Aug 17, 2026

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By